LPS-induced release of IL-1 beta, IL-1Ra, IL-6, and TNF-alpha in whole blood from patients with familial hypercholesterolemia: no effect of cholesterol-lowering treatment.

Proinflammatory cytokines, such as interleukin-1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha (TNF-alpha), are suggested to have an important role in the process of atherosclerosis. Patients with heterozygous familial hypercholesterolemia (FH) have a marked elevation in the plasma level of low-density lipoproteins (LDL), and they show early development of atherosclerosis. The aim of the present study was to test with a whole blood culture system if hyperlipoproteinemia is associated with increased cytokine production capacity in these patients and if treatment with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors influences this production capacity of blood cells, at both the protein and mRNA levels. The capacity of blood cells in a whole blood culture to produce IL-1beta, IL-6, TNF-alpha, IL-12, IL-18, and IL-1 receptor antagonist (IL-1Ra) in response to lipopolysaccharide (LPS) appeared to be similar for heterozygous FH patients and healthy volunteers. Furthermore, the capacity to produce IL-1beta, IL-6, and TNF-alpha in response to LPS was not modified by cholesterol synthesis inhibitors at the level of mRNA expression or at the level of release. On the other hand, the release of IL-1Ra was significantly increased after treatment with HMG-CoA reductase inhibitors, although only at the protein level. This suggests a possible beneficial anti-inflammatory role for this therapy.

[1]  M. Netea,et al.  LPS-induced cytokine production and expression of beta2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia. , 1998, Atherosclerosis.

[2]  M. Netea,et al.  LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors. , 1998, Atherosclerosis.

[3]  M. Wurfel,et al.  Targeted Deletion of the Lipopolysaccharide (LPS)-binding Protein Gene Leads to Profound Suppression of LPS Responses Ex Vivo, whereas In Vivo Responses Remain Intact , 1997, The Journal of experimental medicine.

[4]  A. Namboodiri,et al.  Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. , 1997, The Journal of clinical investigation.

[5]  G. Rune,et al.  Lipopolysaccharide-binding protein is required to combat a murine Gram-negative bacterial infection , 1997, Nature.

[6]  M. Gerritsen,et al.  Low-density lipoprotein receptor knockout mice exhibit exaggerated microvascular responses to inflammatory stimuli. , 1997, Circulation research.

[7]  M. Netea,et al.  A semi-quantitative reverse transcriptase polymerase chain reaction method for measurement of MRNA for TNF-alpha and IL-1 beta in whole blood cultures: its application in typhoid fever and exentric exercise. , 1996, Cytokine.

[8]  M. Netea,et al.  Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections. , 1996, The Journal of clinical investigation.

[9]  S. Van Uum,et al.  Endurance run increases circulating IL-6 and IL-1ra but downregulates ex vivo TNF-alpha and IL-1 beta production. , 1995, Journal of applied physiology.

[10]  B. Kasiske,et al.  Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin. , 1995, Kidney international.

[11]  C. Grunfeld,et al.  Increased lipopolysaccharide‐induced tumour necrosis factor levels and death in hypercholesterolaemic rabbits , 1995 .

[12]  T. Yue,et al.  Interleukin-1β induces expression of adhesion molecules in human vascular smooth muscle cells and enhances adhesion of leukocytes to smooth muscle cells , 1995 .

[13]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[14]  J. E. Pedersen,et al.  Inhalation of levomepromazine in severe acute asthma , 1994, The Lancet.

[15]  U. Ikeda,et al.  Involvement of adhesion molecules in human monocyte adhesion to and transmigration through endothelial cells in vitro. , 1994, Atherosclerosis.

[16]  R. Terkeltaub,et al.  Role of the mevalonate pathway of isoprenoid synthesis in IL‐8 generation by activated monocytic cells , 1994, Journal of leukocyte biology.

[17]  Lopes-Virella Mf.  Interactions between bacterial lipopolysaccharides and serum lipoproteins and their possible role in coronary heart disease. , 1993 .

[18]  J. Berliner,et al.  The role of oxidized low-density lipoprotein in atherogenesis , 1993 .

[19]  J. D. Baum,et al.  Cholesterol regulates the cell surface expression of glycophospholipid-anchored CD14 antigen on human monocytes. , 1993, Biochimica et biophysica acta.

[20]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[21]  P. Conti,et al.  Effect of interleukin-1 receptor antagonist on vascular smooth muscle cell proliferation. , 1993, Atherosclerosis.

[22]  L. Moldawer,et al.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  H. Pan,et al.  Comparative Pharmacokinetics and Pharmacodynamics of Pravastatin and Lovastatin , 1990, Journal of clinical pharmacology.

[24]  M. Jäättelä,et al.  Phagocyte Function in Familial Hypercholesterolaemia: Peripheral Blood Monocytes Exposed to Lipopolysaccharide Show Increased Tumour Necrosis Factor Production , 1990, Scandinavian journal of immunology.

[25]  K. Hasegawa,et al.  Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. , 1990, Biochimica et biophysica acta.

[26]  D. Morel,et al.  Superoxide anion participation in human monocyte-mediated oxidation of low-density lipoprotein and conversion of low-density lipoprotein to a cytotoxin. , 1989, Journal of immunology.

[27]  M. Nieminen,et al.  SEROLOGICAL EVIDENCE OF AN ASSOCIATION OF A NOVEL CHLAMYDIA, TWAR, WITH CHRONIC CORONARY HEART DISEASE AND ACUTE MYOCARDIAL INFARCTION , 1988, The Lancet.

[28]  A. Endo.  Chemistry, biochemistry, and pharmacology of HMG-CoA reductase inhibitors , 1988, Klinische Wochenschrift.

[29]  J. Berliner,et al.  Low density lipoproteins transfer bacterial lipopolysaccharides across endothelial monolayers in a biologically active form. , 1988, The Journal of clinical investigation.

[30]  P. Edwards,et al.  The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[31]  P. Demacker,et al.  Five methods for determining low-density lipoprotein cholesterol compared. , 1984, Clinical chemistry.

[32]  J. Logel,et al.  Inhibition of degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by mevinolin. , 1983, The Journal of biological chemistry.

[33]  M. Reidy,et al.  Distortion of endothelial repair. The effect of hypercholesterolaemia on regeneration of aortic endothelium following injury by endotoxin. A scanning electron microscope study. , 1978, Atherosclerosis.

[34]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[35]  G. Wick,et al.  Coexpression of heat-shock protein 60 and intercellular-adhesion molecule-1 is related to increased adhesion of monocytes and T cells to aortic endothelium of rats in response to endotoxin. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[36]  P. Libby,et al.  Regulation of smooth muscle cell scavenger receptor expression in vivo by atherogenic diets and in vitro by cytokines. , 1995, The Journal of clinical investigation.

[37]  W. Lynn,et al.  Adjunctive therapy for septic shock: a review of experimental approaches. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  P. Libby,et al.  Cytokines Regulate Vascular Functions Related to Stability of the Atherosclerotic Plaque , 1995, Journal of cardiovascular pharmacology.

[39]  S. Ylä-Herttuala,et al.  Macrophages and oxidized low density lipoproteins in the pathogenesis of atherosclerosis. , 1991, Annals of medicine.